Table 1.
Demographic and Clinical Features of MIS-C Patients
| MIS-C 1 | MIS-C 2 | MIS-C 3 | MIS-C 4 | MIS-C 5 | MIS-C 6 | MIS-C 7 | MIS-C 8 | MIS-C 9 | Aggregate | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Male | Female | Male | Female | Male | Male | Female | Female | Female | 4/9 Male | |
| Age range (years) | 0–6 | 7–13 | 7–13 | 0–6 | 14–20 | 7–13 | 7–13 | 7–13 | 14–20 | Median 12 years old | |
| Ethnicity | Hispanic | Hispanic | Black | Hispanic | N/A | Hispanic | Black | Hispanic | Hispanic | 6/8 Hispanic, 2/8 Black | |
| Comorbidities | None | None | Asthma | None | Asthma | None | MDD, PTSD | None | None | 3/9 | |
| WHO MIS-C Criteria∗ | + | + | + | + | + | + | + | + | + | 9/9 | |
| Fever | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 | |
| Rash | No | Yes | No | Yes | Yes | No | No | No | No | 3/9 | |
| Conjunctivitis | Yes | Yes | No | No | No | No | No | Yes | No | 3/9 | |
| Mucocutaneous | Yes | Yes | No | Yes | No | No | No | No | No | 3/9 | |
| Extremity | No | No | No | No | No | No | No | No | No | 0/9 | |
| Gastrointestinal | Pain, emesis | Pain, emesis | Pain | Emesis, diarrhea | Diarrhea | Pain | Emesis, diarhhea | Pain, emesis | No | 8/9 | |
| Hypotension / shock | Yes | Yes | No | No | No | Yes | Yes | Yes | No | 5/9 | |
| Cardiac Abnormalities(↑↑) | Troponin, BNP, CA dilation, MR | Troponin, BNP | Troponin, BNP, prolonged-PR, CM | Troponin, BNP | CA ectasia | Troponin, BNP, CA dilation | Troponin, BNP, CA aneurysm, reduced LV function, diffuse ST elevation | Troponin, BNP, CA aneurysm, reduced LV function, prolonged QT | BNP, CA dilation, reduced LV function, MR | 9/9 | |
| Coagulopathy(↑↑) | D-dimer, PT, PTT | D-dimer, PT, PTT | D-dimer, PT, PTT | D-dimer, PT, PTT | D-dimer | D-dimer, PT, PTT | D-dimer, PT, PTT | D-dimer, PT, PTT | D-dimer, PT, PTT | 9/9 | |
| Inflammatory Markers(↑↑) | ESR, CRP, PCT | ESR, CRP, PCT | ESR, CRP | ESR, CRP, PCT | ESR, CRP, PCT | ESR, CRP, PCT | ESR, CRP, PCT | ESR, CRP, PCT | ESR, CRP | 9/9 | |
| Other microbial cause | No | No | No | No | No | No | No | No | N/A | 0/8 | |
| CoV-2 PCR | Neg | N/A | Neg | Pos | Pos | Neg | Neg | Neg | Pos | 3/9 | |
| Prior Cov-2 Exposure | N/A | N/A | N/A | Mother PCR+ 3 weeks prior | N/A | PCR+ 4 weeks prior | N/A | N/A | Relatives PCR+ 1-2 months prior | 2/9 | |
| CoV-2 Serology | + | + | + | + | + | + | + | + | + | 9/9 | |
| Other Clinical Features | Scrotal pain, TCP, Trans-aminases, RAD | TCP, Trans-aminases, RAD | SOB, Pleural effusions, Thrombocytosis, Trans-aminases | Thrombo-cytosis, Trans-aminases | SOB, Headache, Hypertension, Pneumonia, Trans-aminases, RAD | Appendictis 4 weeks prior, Trans-aminases | Headache, Thrombo-cytosis, Trans-aminases | Headache, Trans-aminases, Hyper-triglyceridemia | Headache | ||
| Treatment | IVIG x1, TCZ x3, enoxaparin, ASA | IVIG x2, enoxaparin, ASA | TCZ x1, enoxaparin, ASA | IVIG x1, TCZ x2, enoxaparin | IVIG x1, TCZ x1, enoxaparin | IVIG x1, TCZ x2, enoxaparin, ASA | IVIG x1, TCZ x1, enoxaparin | IVIG x1, TCZ x1, enoxaparin, ASA, hydrocortisone | IVIG x1, enoxaparin, ASA | ||
| Admission duration (days) | 8 | 6 | 6 | 5 | 3 | 8 | 6 | 5 | 4 | Median 6 days | |
| Outcome | Favorable | Favorable | Favorable | Favorable | Favorable | Favorable | Favorable | Favorable | Favorable | Favorable | |
Demographic and clinical features of MIS-C patients (N = 9). For privacy concerns, patient ages are grouped into three bins (0–6, 7–13, 14–20 years old) rather than providing exact values. Abbreviations: coronary artery, CA; major depressive disorder, MDD; post-traumatic stress disorder, PTSD; cardiomegaly, CM; mitral regurgitation, MR; left ventricle, LV; thrombocytopenia, TCP; reactive airway disease, RAD; shortness of breath, SOB; intravenous immunoglobulin, IVIG; tocilizumab, TCZ; acetylsalicylic acid, ASA. See also Figure S1 and S2 and Table S1.